Covered recipient · General Payments record
BRIAN R WEBSTER
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$344.12
25 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $344.12 | 25 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk Inc | $109.73 | 8 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $49.29 | 3 |
| Lilly USA, LLC | $38.09 | 3 |
| Amgen Inc. | $27.62 | 2 |
| Dynavax Technologies Corporation | $18.14 | 1 |
| Arbor Pharmaceuticals, Inc. | $14.85 | 1 |
| Kowa Pharmaceuticals America, Inc. | $13.85 | 1 |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | $13.01 | 1 |
| GlaxoSmithKline, LLC. | $12.59 | 1 |
| PFIZER INC. | $12.00 | 1 |
| IRONWOOD PHARMACEUTICALS, INC | $11.86 | 1 |
| Janssen Pharmaceuticals, Inc | $11.58 | 1 |
| SANOFI-AVENTIS U.S. LLC | $11.51 | 1 |
Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRIAN R WEBSTER
NPI 1124129671 · CMS profile ID 187421
Allopathic & Osteopathic Physicians / Internal Medicine
WILMINGTON, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
25 matching records · $344.12 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–25 of 25.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.08 | 11/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720467485 | CMS |
| Novo Nordisk Inc | $5.71 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744899649 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.79 | 09/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720467489 | CMS |
| Novo Nordisk Inc | $25.00 | 08/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744841789 | CMS |
| Novo Nordisk Inc | $12.04 | 08/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744814309 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $11.86 | 07/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749817371 | CMS |
| Novo Nordisk Inc | $6.21 | 06/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744757523 | CMS |
| Novo Nordisk Inc | $16.23 | 05/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744693681 | CMS |
| Kowa Pharmaceuticals America, Inc. | $13.85 | 03/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 716723711 | CMS |
| Lilly USA, LLC | $13.84 | 03/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728356859 | CMS |
| SANOFI-AVENTIS U.S. LLC | $11.51 | 03/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744156151 | CMS |
| Dynavax Technologies Corporation | $18.14 | 03/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747407237 | CMS |
| Lilly USA, LLC | $11.60 | 02/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728356857 | CMS |
| Amgen Inc. | $12.97 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740942163 | CMS |
| Janssen Pharmaceuticals, Inc | $11.58 | 02/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719062941 | CMS |
| Novo Nordisk Inc | $17.31 | 02/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744730465 | CMS |
| Novo Nordisk Inc | $14.25 | 02/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744596247 | CMS |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | $13.01 | 02/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747893453 | CMS |
| GlaxoSmithKline, LLC. | $12.59 | 02/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738645835 | CMS |
| Arbor Pharmaceuticals, Inc. | $14.85 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735747095 | CMS |
| Amgen Inc. | $14.65 | 01/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740942161 | CMS |
| Lilly USA, LLC | $12.65 | 01/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728370465 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.42 | 01/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720467493 | CMS |
| Novo Nordisk Inc | $12.98 | 01/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744555867 | CMS |
| PFIZER INC. | $12.00 | 01/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743661937 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,179,650.03 | 45 |
| PY2024 | Principal investigator | $1,336,794.36 | 51 |
| PY2023 | Recipient | $628.25 | 1 |
| PY2023 | Principal investigator | $421,175.77 | 35 |
| PY2022 | Principal investigator | $414,800.07 | 178 |
| PY2021 | Principal investigator | $249,631.83 | 98 |
| PY2020 | Principal investigator | $39,638.70 | 30 |
| PY2019 | Principal investigator | $10,918.41 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
98 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417131 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417133 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417177 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417179 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417181 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417183 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417185 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417187 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417189 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417191 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417193 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417195 |
| Principal investigator 1 | Esperion Therapeutics, Inc. | $239.00 | 12/17/2021 | Non-covered Recipient Entity WILMINGTON HEALTH PLLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT | No dispute reported | 06/30/2026 | 838455969 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,395.90 | 12/15/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809493373 |
| Principal investigator 1 | PFIZER INC. | $4,274.11 | 12/07/2021 | Non-covered Recipient Entity Innovo Research Inc | A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 | No dispute reported | 06/30/2026 | 832557437 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417127 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417129 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417157 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417159 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417161 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417163 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417165 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417167 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417169 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417171 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417173 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/30/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417175 |
| Principal investigator 1 | PFIZER INC. | $7,394.29 | 11/30/2021 | Non-covered Recipient Entity Innovo Research Inc | A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 | No dispute reported | 06/30/2026 | 832668759 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $787.50 | 11/24/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809493375 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,015.10 | 11/17/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809493347 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $945.00 | 11/01/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809499107 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,091.70 | 11/01/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809518007 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417115 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417117 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417135 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417137 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417139 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417141 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417143 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417145 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417147 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417149 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417151 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/29/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417153 |
| Principal investigator 1 | PFIZER INC. | $1,269.00 | 10/29/2021 | Non-covered Recipient Entity Innovo Research Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832832317 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $176.00 | 10/26/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417113 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $88.00 | 10/26/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417125 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $176.00 | 10/24/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417105 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $198.00 | 10/24/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417107 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $132.00 | 10/24/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417109 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $70.00 | 10/24/2021 | Non-covered Recipient Entity Wilmington Health | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 828417111 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $88.00 | 10/24/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417119 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $66.00 | 10/24/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417121 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1.40 | 10/24/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417123 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $66.00 | 10/24/2021 | Non-covered Recipient Entity Wilmington Health | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension | No dispute reported | 06/30/2026 | 828417155 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $630.00 | 10/20/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809518043 |
| Principal investigator 1 | Janssen Research & Development, LLC | $38.00 | 10/18/2021 | Non-covered Recipient Entity Wilmington Hlth Pllc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787847805 |
| Principal investigator 1 | Janssen Research & Development, LLC | $184.00 | 10/18/2021 | Non-covered Recipient Entity Wilmington Hlth Pllc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787847817 |
| Principal investigator 1 | Janssen Research & Development, LLC | $387.00 | 10/18/2021 | Non-covered Recipient Entity Wilmington Hlth Pllc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787847829 |
| Principal investigator 1 | Janssen Research & Development, LLC | $869.00 | 10/18/2021 | Non-covered Recipient Entity Wilmington Hlth Pllc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787847839 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,417.50 | 10/13/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809499101 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,102.50 | 10/06/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809518013 |
| Principal investigator 1 | PFIZER INC. | $1,123.20 | 10/05/2021 | Non-covered Recipient Entity Innovo Research Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832765999 |
| Principal investigator 1 | PFIZER INC. | $14,000.00 | 10/01/2021 | Non-covered Recipient Entity Innovo Research Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832809261 |
| Principal investigator 1 | PFIZER INC. | $4,747.28 | 10/01/2021 | Non-covered Recipient Entity Innovo Research Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832841675 |
| Principal investigator 1 | PFIZER INC. | $14,000.00 | 09/21/2021 | Non-covered Recipient Entity Innovo Research Inc | A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 | No dispute reported | 06/30/2026 | 832668751 |
| Principal investigator 1 | PFIZER INC. | $14,000.00 | 09/21/2021 | Non-covered Recipient Entity Innovo Research Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832761600 |
| Principal investigator 1 | PFIZER INC. | $920.00 | 09/17/2021 | Non-covered Recipient Entity INNOVO RESEARCH WILMINGTON HEALTH | A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 | No dispute reported | 06/30/2026 | 832578341 |
| Principal investigator 1 | PFIZER INC. | $113.80 | 09/17/2021 | Non-covered Recipient Entity INNOVO RESEARCH WILMINGTON HEALTH | A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 | No dispute reported | 06/30/2026 | 832578349 |
| Principal investigator 1 | PFIZER INC. | $917.00 | 08/11/2021 | Non-covered Recipient Entity INNOVO RESEARCH WILMINGTON HEALTH | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 832860957 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $945.00 | 08/10/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485123 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $630.00 | 08/10/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809511889 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $630.00 | 08/10/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809512017 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $787.50 | 08/03/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809511895 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,575.00 | 07/14/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485127 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $787.50 | 07/14/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485129 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19.00 | 06/25/2021 | Non-covered Recipient Entity Qcare Site Svcs Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787746218 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,260.00 | 06/23/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485657 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,260.00 | 06/09/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809511877 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,388.00 | 05/25/2021 | Non-covered Recipient Entity Qcare Site Svcs Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787746205 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,204.00 | 05/24/2021 | Non-covered Recipient Entity Qcare Site Svcs Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787746183 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $630.00 | 05/19/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485663 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,417.50 | 05/12/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485627 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $787.50 | 05/05/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809511883 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,733.00 | 04/27/2021 | Non-covered Recipient Entity Qcare Site Svcs Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787746162 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $945.00 | 04/21/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485125 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $630.00 | 04/21/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485665 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $630.00 | 04/07/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485659 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $787.50 | 04/07/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809491633 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $787.50 | 04/01/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485121 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,526.00 | 03/24/2021 | Non-covered Recipient Entity Qcare Site Svcs Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787746023 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,890.00 | 03/17/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809491629 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $630.00 | 03/17/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809511865 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $787.50 | 02/23/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809511871 |
| Principal investigator 1 | AstraZeneca UK Limited | $83,347.05 | 02/22/2021 | Non-covered Recipient Entity WILMINGTON HEALTH | A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 | No dispute reported | 06/30/2026 | 826472293 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $945.00 | 02/17/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809485661 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,575.00 | 02/03/2021 | Non-covered Recipient Entity PMG RESEARCH INC | Not supplied | No dispute reported | 06/30/2026 | 809491631 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $945.00 | 01/04/2021 | Non-covered Recipient Entity PMG RESEARCH INC | EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S | No dispute reported | 06/30/2026 | 860871395 |